Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Shares Issued (2020 - 2025)

Harmony Biosciences Holdings' Shares Issued history spans 6 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Shares Issued fell 18.2% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $10.2 million, up 56.98%, while the annual FY2025 figure was $10.2 million, 56.98% up from the prior year.
  • Shares Issued for Q4 2025 was $2.6 million at Harmony Biosciences Holdings, up from $754000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $8.4 million in Q4 2022 and bottomed at -$2.7 million in Q3 2022.
  • The 5-year median for Shares Issued is $1.2 million (2021), against an average of $2.0 million.
  • The largest YoY upside for Shares Issued was 15591.67% in 2022 against a maximum downside of 340.3% in 2022.
  • A 5-year view of Shares Issued shows it stood at $7.6 million in 2021, then grew by 11.3% to $8.4 million in 2022, then crashed by 97.31% to $227000.0 in 2023, then surged by 1325.99% to $3.2 million in 2024, then fell by 18.2% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Shares Issued are $2.6 million (Q4 2025), $754000.0 (Q3 2025), and $2.1 million (Q2 2025).